Premium
SAFETY ANALYSIS OF PATIENTS WITH A MEDICAL HISTORY OF RESPIRATORY DISORDERS TREATED WITH COPANLISIB FROM THE CHRONOS‐1 STUDY IN RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA
Author(s) -
Zinzani P.L.,
Santoro A.,
Leppä S.,
Demeter J.,
Follows G.A.,
Lenz G.,
Kim W.S.,
Mollica L.,
Nagler A.,
Phipps Diong C.,
Provencio M.,
Magagnoli M.,
Munoz J.,
Miriyala A.,
Liu L.,
Zhang M.,
GarciaVargas J.,
Childs B.H.,
Dreyling M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.58_2631
Subject(s) - medicine , ofatumumab , idelalisib , regimen , adverse effect , bendamustine , follicular lymphoma , meddra , obinutuzumab , rituximab , lymphoma , leukemia , chronic lymphocytic leukemia , ibrutinib , pharmacovigilance